Supporting Information

Figure S1. Result of 04L OOR protofibrils after equilibration MD simulation.



(a) Conformation change results of 04L OOR protofibrils; first trial (black), second trial (red) and third trial (blue) after 50ns equilibration MD simulations. (b) RMSD data of 04L OOR protofibrils during 50 ns equilibration simulation. (c) RMSF data of each residue of 04L OOR protofibrils during the last 5ns of equilibration simulation.

Figure S2. Result of 06L OOR protofibrils after equilibration MD simulation.



(a) Conformation change results of 06L OOR protofibrils; first trial (black), second trial (red) and third trial (blue) after 50ns equilibration MD simulations. (b) RMSD data of 06L OOR protofibrils during 50 ns equilibration simulation. (c) RMSF data of each residue of 06L OOR protofibrils at last 5ns of equilibration simulation.

Figure S3. Result of 08L OOR protofibrils after equilibration MD simulation.



(a) Conformation change results of 08L OOR protofibrils; first trial (black), second trial (red) and third trial (blue) after 50ns equilibration MD simulations. (b) RMSD data of 08L OOR protofibrils during 50 ns equilibration simulation. (c) RMSF data of each residue of 08L OOR protofibrils at last 5ns of equilibration simulation.

Figure S4. Result of 10L OOR protofibrils after equilibration MD simulation.



(a) Conformation change results of 10L OOR protofibrils; first trial (black), second trial (red) and third trial (blue) after 50ns equilibration MD simulations. (b) RMSD data of 10L OOR protofibrils during 50 ns equilibration simulation. (c) RMSF data of each residue of 10L OOR protofibrils at last 5ns of equilibration simulation.

Figure S5. Result of 12L OOR protofibrils after equilibration MD simulation.



(a) Conformation change results of 12L OOR protofibrils; first trial (black), second trial (red) and third trial (blue) after 50ns equilibration MD simulations. (b) RMSD data of 12L OOR protofibrils during 50 ns equilibration simulation. (c) RMSF data of each residue of 12L OOR protofibrils at last 5ns of equilibration simulation.

Figure S6. Result of 14L OOR protofibrils after equilibration MD simulation.



(a) Conformation change results of 14L OOR protofibrils; first trial (black), second trial (red) and third trial (blue) after 50ns equilibration MD simulations. (b) RMSD data of 14L OOR protofibrils during 50 ns equilibration simulation. (c) RMSF data of each residue of 14L OOR protofibrils at last 5ns of equilibration simulation.

Figure S7. RMSF data of each residue of IAPP OOR fibrils.



Temperature factor of amyloid forming peptide NFGAILS of Islet Amyloid Polypeptide (PDB ID: 5E5V) obtained from the experimental results of Soriaga et al. (black) Average RMSF data from our computational works from 04L to 10L model. (red)